CABA Aug 2024 10.000 call
| Previous close | 0.9000 |
| Open | 0.7500 |
| Bid | 0.4500 |
| Ask | 3.3000 |
| Strike | 10.00 |
| Expiry date | 2024-08-16 |
| Day's range | 0.7500 - 0.9000 |
| Contract range | N/A |
| Volume | |
| Open interest | 75 |
GlobeNewswireCabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both patients by day 15 post-infusion – – Improvements in both patients’ specific disease measures, consistent with academic experience of a similar 4-1BB CD19-CAR T, suggest emerging clinical benefit with CABA-201 while discontinuing all
- GlobeNewswire
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
PHILADELPHIA, May 29, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 11:00 a.m. ET in New York, NY. A live webcast of the
Simply Wall St.We Think Cabaletta Bio (NASDAQ:CABA) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
